🔒 Q2 2025 earnings call 2025-05-07 NEWEST
Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.
Our AI read all 38 of EMR's earnings calls (2016–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.
Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.
Management held guidance steady against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics.
Management held guidance steady against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics, frequently evasive.
Management raised guidance against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.
Management raised guidance against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics.
Management raised guidance against steady demand and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.
Management held guidance steady against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.
Management raised guidance against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.
| Call | Date | Grade | Guidance | Demand | Margins | Candor | Evasion |
|---|---|---|---|---|---|---|---|
| Q2 2023 | 2023-05-03 | B+ | raised | mixed | expanding | 7/9 | 2/9 |
| Q1 2023 | 2023-02-08 | C+ | maintained | stable | expanding | 7/9 | 3/9 |
| Q4 2022 | 2022-11-02 | B | maintained | accelerating | expanding | 7/9 | 3/9 |
| Q3 2022 | 2022-08-09 | C | lowered | stable | expanding | 7/9 | 2/9 |
| Q2 2022 | 2022-05-04 | B+ | raised | accelerating | expanding | 7/9 | 2/9 |
| Q1 2022 | 2022-02-02 | B+ | raised | accelerating | mixed | 8/9 | 2/9 |
| Nov 2021 | 2021-11-03 | C+ | maintained | accelerating | contracting | 7/9 | 3/9 |
| Q3 2021 | 2021-08-04 | B+ | raised | accelerating | expanding | 8/9 | 2/9 |
| Q2 2021 | 2021-05-05 | A | raised | accelerating | expanding | 8/9 | 1/9 |
| Q1 2021 | 2021-02-03 | A | raised | accelerating | expanding | 7/9 | 3/9 |
| Q4 2020 | 2020-11-03 | C+ | maintained | mixed | expanding | 7/9 | 2/9 |
| Q3 2020 | 2020-08-04 | A | raised | mixed | contracting | 8/9 | 1/9 |
| Q2 2020 | 2020-04-22 | C+ | lowered | slowing | stable | 8/9 | 1/9 |
| Q1 2020 | 2020-02-04 | B+ | raised | mixed | contracting | 8/9 | 2/9 |
| Q4 2019 | 2019-11-06 | D | lowered | slowing | expanding | 8/9 | 2/9 |
| Q3 2019 | 2019-08-06 | C | lowered | slowing | contracting | 8/9 | 2/9 |
| Q2 2019 | 2019-05-07 | C | lowered | slowing | contracting | 8/9 | 2/9 |
| Q1 2019 | 2019-02-05 | A | raised | mixed | contracting | 8/9 | 2/9 |
| Q4 2018 | 2018-11-07 | B | maintained | stable | expanding | 7/9 | 2/9 |
| Q3 2018 | 2018-08-07 | A | raised | accelerating | expanding | 7/9 | 2/9 |
| Q2 2018 | 2018-05-02 | A | raised | accelerating | expanding | 8/9 | 1/9 |
| Q1 2018 | 2018-02-06 | A | raised | accelerating | expanding | 8/9 | 1/9 |
| Q4 2017 | 2017-11-08 | C | maintained | accelerating | expanding | 6/9 | 4/9 |
| Q3 2017 | 2017-08-01 | B+ | raised | accelerating | expanding | 8/9 | 1/9 |
| Q2 2017 | 2017-05-02 | A | raised | accelerating | expanding | 8/9 | 2/9 |
| Q1 2017 | 2017-02-07 | A | raised | accelerating | expanding | 7/9 | 2/9 |
| Q4 2016 | 2016-11-01 | C+ | lowered | mixed | expanding | 8/9 | 2/9 |
| Q3 2016 | 2016-08-02 | D | lowered | slowing | contracting | 8/9 | 5/9 |
| Q2 2016 | 2016-05-03 | B | maintained | mixed | expanding | 8/9 | 3/9 |
| Q1 2016 | 2016-02-02 | D | maintained | slowing | contracting | 8/9 | 3/9 |
During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of EMR's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.
The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.
← EMP.A All “E” companies EMRAF →